[Paleopsych] Kenan Malik: Is this the future we really want? Different drugs for different races
shovland at mindspring.com
shovland at mindspring.com
Sat Jul 23 18:21:20 UTC 2005
There are also sex differences and possibly age differences.
The medicine of the future will be custom medicine, tailored
to the individual on the basis of careful testing, rather than
the shotgun approach we use now.
From: "Lynn D. Johnson, Ph.D." <ljohnson at solution-consulting.com>
Sent: Jul 23, 2005 6:34 PM
To: The new improved paleopsych list <paleopsych at paleopsych.org>
Subject: Re: [Paleopsych] Kenan Malik: Is this the future we really want? Different drugs for different races
It seems like a good future to me. I am not going to do a complete
exegesis on this, but offer one point.
Malik's warning: "One of the dangers of marketing BiDiL as
a black drug is that it may be given to African-Americans who don't
respond to it, but denied to non-blacks who could." is an example
of illogic. There is no medical rationale for giving the drug to
non-African Americans since that was the only group with a
stiatistically robust response. In the American Psychological
Association the Received Wisdom is that there is no such thing as race,
yet in medicine there are some differences. It is not biology that makes
them argue this way, IMHO, but Political Correct Thinking. The idea
behind PC talk is that we could change reality by changing our discourse
- the constructivism POV. In my view, truth is quite approachable in
this life, and we ought to be about it, and I am not convinced we can
reframe all reality away.
Contradictory thoughts are welcomed.
Premise Checker wrote:
> Kenan Malik: Is this the future we really want? Different drugs for
> different races
> The Times Online guest contributors Opinion
> A US GOVERNMENT advisory panel recommended this week that a drug
> helps to treat congestive heart failure should be granted a licence.
> Its decision is controversial because BiDiL will be the first
> racially-targeted drug. When tested on the general population it
> proved ineffective, but when given to African-Americans, to whom it
> will be marketed, it appeared to cut death rates from heart
> failure by
> 43 per cent.
> The BiDiL debate gets to the heart of one of the most explosive
> in medicine. Does race matter in medicine? Or should it be
> The New England Journal of Medicine has argued that "race is
> biologically meaningless" and that doctors should be taught about
> dangers inherent in practising race-based medicine." Others disagree.
> The psychiatrist, Sally Satel, believes that in medicine
> often works". In her Washington drug clinic, Satel prescribes
> different amounts of Prozac to black and white patients because, she
> says, the two groups seem to meta bolise antidepressants at different
> So who is right? As with much else in debates about race, the answer
> is both sides and neither. Different populations do show different
> patterns of disease and disorder. Northern Europeans, for instance,
> are more likely to suffer from cystic fibrosis than other groups.
> Tay-Sachs, a fatal disease of the central nervous system,
> affects Ashkenazi Jews. Beta-blockers appear to work less effectively
> for African-Americans than those of European descent.
> Yet race is not necessarily a good guide to disease. We all think we
> know that sickle-cell anaemia is a black disease. Except that it is
> not. Sickle cell is a disease of populations originating from areas
> with a high incidence of malaria. Some of these populations are
> some are not. The sickle-cell gene is found in equatorial Africa,
> parts of southern Europe, southern Turkey, parts of the Middle East
> and much of central India. Most people, however, only know that
> African-Americans suffer disproportionately from the trait. And,
> popular ideas about race, they automatically assume that what applies
> to black Americans also applies to all blacks and only to blacks. It
> is the social imagination, not the biological reality, of race that
> turns sickle cell into a black disease.
> Genetic studies show that human beings comprise a relatively
> homogenous species and that most of our genetic variation is at
> individual, not group, level. Imagine that a nuclear explosion wiped
> out the human race apart from one small population -- say, the Masai
> tribe in East Africa. Virtually all the genetic variation that exists
> in the world today would still be present in that one small group.
> About 85 per cent of human variation occurs between individuals
> local populations. A further 10 per cent or so differentiates
> populations within a race. Only about 5 per cent of total variation
> distinguishes the major races. This is why many scientists reject the
> idea of race.
> Since most variation exists at the individual level, doctors ideally
> would like to map every individual's genome to be able to predict
> better his potential medical problems and responses to different
> drugs. Such individual genotyping is currently both impracticable and
> too costly, so doctors often resort to using surrogate indicators of
> an individual's risk profile -- such as race.
> Until recently people were more likely to marry a neighbour than
> someone who hailed from distant lands. As a result the farther apart
> two populations are geographically, the more distinct they are likely
> to be genetically. Icelanders are genetically different from Greeks,
> but they are genetically closer to Greeks than they are to Nigerians.
> The difference is tiny, but it can have a medical impact. Knowing the
> population from which your ancestors came can provide hints as to
> genes you may be carrying. Hence race, which Satel suggests, is a
> "poor man's clue" in medicine.
> But a poor man's clue may be about as reliable as an intelligence
> dossier. First, there are no hard and fast divisions between
> populations. Every population runs into another and no gene is unique
> to one. Cystic fibrosis may be more common among northern Europeans
> but is not confined to them. One of the dangers of marketing BiDiL as
> a black drug is that it may be given to African-Americans who don't
> respond to it, but denied to non-blacks who could. Secondly,
> genes are distributed differently among populations. The pattern of
> distribution of genes for cystic fibrosis is not the same as that of
> sickle-cell genes. Which population differences are important varies
> from one disease to another. Finally, many medical differences
> associated with race are likely to be the result of environmental
> rather than genetic differences, or a combination of the two. In the
> case of response to BiDiL, no one knows which is more important.
> All this suggests that the question of whether medicine should be
> colourblind depends on the particular problem we want to address. It
> is a pragmatic issue, not one rooted in scientific or political
> principle. Race, however, is such a contentious issue that pragmatism
> rarely enters the debate. On one side, so-called race realists think
> that population differences are so important that all medicine should
> be colour-coded. On the other, many antiracists want to ban
> research entirely for fear of its social consequences. Both are
> It is time everyone calmed down and took a grown-up view of the
> Kenan Malik is author of Man, Beast and Zombie: What Science Can and
> Cannot Tell Us about Human Nature
> paleopsych mailing list
> paleopsych at paleopsych.org
paleopsych mailing list
paleopsych at paleopsych.org
More information about the paleopsych